illustrates how AstraZeneca has used business development to expand its cell-therapy capabilities beyond chimeric antigen receptor T cells (CAR-Ts) and move into new areas. “I think a ...
AstraZeneca overhauls management of its China ... In this Viewsroom podcast, Breakingviews columnists share predictions for how robotic cars, obesity drug-fueled M&A or a smartphone backlash ...